XML 22 R3.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 70,456 $ 110,662
Restricted cash 1,396 1,738
Research and development incentives receivable 1,108 7,139
Prepaid expenses and other current assets 4,830 6,203
Total current assets 77,790 125,742
Property and equipment, net 3,523 7,373
Intangible assets, net 14,288 21,947
Right of use assets, net 1,638 4,384
Other assets 930 881
Total assets 98,169 160,327
Current liabilities:    
Accounts payable 350 2,474
Accrued expenses and other current liabilities 6,249 9,525
Deferred income 1,396 1,738
Operating lease liability - current 2,023 1,920
Total current liabilities 10,018 15,657
Non-current liabilities:    
Operating lease liability - non-current 9,258 10,087
Contingent consideration 2,871 2,650
Other non-current liabilities 1,476 1,360
Deferred tax liability, net 254 438
Total liabilities 23,877 30,192
Commitments and contingencies (Note 16)
Stockholders’ equity:    
Ordinary shares, £0.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663) 1 1
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443) 86 86
Additional paid-in capital 393,944 393,474
Accumulated deficit (304,092) (237,664)
Accumulated other comprehensive loss – foreign currency translation adjustments (15,731) (25,868)
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders 74,208 130,029
Noncontrolling interest 84 106
Total stockholders’ equity 74,292 130,135
Total liabilities and stockholders’ equity $ 98,169 $ 160,327